Investigation of nicotinamide as more than an anti-phosphorus drug in chronic hemodialysis patients: a single-center, double-blind, randomized, placebo-controlled trial

BACKGROUND: Hyperphosphatemia is a common complication of late-stage chronic kidney disease (CKD). Nicotinamide (NAM) has been reported as an adjunctive therapy for hyperphosphatasemia, but the effect of NAM on fibroblast growth factor 23 (FGF23) and Klotho has rarely been reported. METHODS: We rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xiang-Yang, Yao, Jing-Rui, Xu, Rong, Xu, Lin-Xin, Zhang, Yue-Feng, Lu, Shan, Xing, Zhi-Heng, Fan, Li-Ping, Qin, Zhong-Hua, Sun, Bei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214904/
https://www.ncbi.nlm.nih.gov/pubmed/32411753
http://dx.doi.org/10.21037/atm.2020.03.228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214904/
https://www.ncbi.nlm.nih.gov/pubmed/32411753
http://dx.doi.org/10.21037/atm.2020.03.228

Ejemplares similares